# A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct07441512/  
OnCo record `nct07441512` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of inavolisib and eribulin in triple-negative breast cancer, run by Hu Hai, not yet recruiting.

## Summary

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation is a phase 2, interventional study registered as NCT07441512 by Hu Hai, with a registry enrolment figure of 26 participants, started 2026-03-15 and due to reach its primary completion in 2028-03-15. Interventions recorded: Inavolisib in Combination With Eribulin. Conditions listed: TNBC - Triple-Negative Breast Cancer; TNBC. Triple-negative eligibility wording from the registry: "* Prior treatment with PARP inhibitors for advanced TNBC". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07441512
- Phase: 2
- Setting: A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
- Sponsor: Hu Hai
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT07441512: https://clinicaltrials.gov/study/NCT07441512

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Eribulin](https://onco.cc/drugs/eribulin/), [Inavolisib](https://onco.cc/drugs/inavolisib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07441512.json